Studies | Study Design | Location | Population | Risk Factor | Diagnosis Criteria | Oda Parameters | n total | n PEa | n PEl | n PEg | n C |
---|---|---|---|---|---|---|---|---|---|---|---|
Hata 1997 [34] | Cross-sectional | Japan | IG:1-3 T | Not reported | a | PI | 76 | 15 | 9 | 6 | 29 |
Belfort 1999 [17] | Cross-sectional | USA | IG: 3 T | Not reported | ACOG | RI | 42 | 18 | 0 | 0 | 24 |
Takata 2002 [11] | Cross-sectional | Japan | IG: 3 T | No | NHBP2000 | RI, PI, PVS, PR, EDV | 99 | 52 | 25 | 27 | 32 |
Ayaz 2003 [19] | Cross-sectional | Turkey | IG: 3 T | No | a | RI, PI | 60 | 30 | 30 | 0 | 30 |
Diniz 2008 [14] | Cross-sectional | Brazil | IG:25-35w | No | NHBP2000 | RI, PI, PVS, PR, EDV | 91 | 40 | 20 | 20 | 51 |
Stein 2009 [30] | Case control | Brazil | IG: 3 T | Yes | NHBP2000 | RI, PI, PVS, PR, EDV, P2 | 32 | 16 | 0 | 0 | 16 |
Brandão2012 [31] | Cross-sectional | Brazil | IG: 2 T | No | NHBP2000 | RI | 81 | 56 | 30 | 26 | 25 |
Oliveira 2013 [32] | Cross-sectional | Brazil | IG:20-40w | No | NHBP2000 | RI, PI, PR | 349 | 60 | 30 | 30 | 289 |
Olantuji 2015 [15] | Prospective case control | Nigeria | IG: maior 20w | No | NHBP2000 | RI, PI, PVS, PR, EDV, P2 | 92 | 42 | 24 | 18 | 50 |
Porto 2017 [18] | Cohort | Brazil | IG: 3 T | Yes | NHBP2000 | RI | 62 | 10 | 10 | 52 | |
Freitas 2018 [33] | Cross-sectional | Brazil | IG: 3 T | No | ACOG | RI, PI, PVS, PR, EDV, P2, VM | 65 | 36 | 23 | 13 | 29 |
Madina 2020 [16] | Cross-sectional | Pakistan | IG: 2 T e 3 T | Yes | Not reported | RI | 60 | 30 | 0 | 0 | 30 |
Ozdemir 2020 [12] | Cross-sectional | Turkey | IG: após 20w | No | NHBP2000 | RI, PI, PVS, PR, EDV, P2, S/D | 100 | 50 | 0 | 0 | 50 |
Diniz 2022 [13] | Cohort | Brazil | IG: 20-41w | No | ISSHP2018 | RI, PI, PVS, PR, EDV, P2 | 266 | 133 | 0 | 0 | 133 |